Multiple Sclerosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Pregnant people who have been diagnosed with Tuberous Sclerosis Complex (TSC) — either through clinical assessment or genetic testing — based on 2021 guidelines
- Pregnant people who have been diagnosed with LAM (Lymphangioleiomyomatosis), a lung condition associated with TSC
- Pregnant people who have an uncertain genetic result in the TSC1 or TSC2 gene (a result where it's unclear whether the gene change causes disease)
- Pregnant people whose unborn baby has been assessed by the trial doctors as having a 50% chance of having TSC
- Pregnant people whose unborn baby has shown signs that may suggest TSC, such as heart tumours (rhabdomyomas), brain lesions (tubers), or a specific type of brain growth (congenital subependymal giant cell astrocytoma) found before birth
- Babies born to a parent who was already enrolled in this trial
Who may not be able to join:
- Pregnant people who do not have TSC themselves but used preimplantation genetic testing (genetic screening of embryos before pregnancy) to test for TSC — unless the trial doctors determine they meet the fourth inclusion criterion above
- Babies diagnosed with TSC whose birth mother was not enrolled in the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: David M Ritter, MD, PhD, Children's Hospital Medical Center, Cincinnati
Phone: 513-636-9669
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety of mTOR inhibitor in Pregnancy -- mTOR inhibitor adherence; Safety of mTOR inhibitor in Pregnancy -- mTOR inhibitor dosing; Safety of mTOR inhibitor in Pregnancy -- side effects; Maternal-Fetal Complications in TSC; Maternal Post-Partum Behavioral Health; Maternal Post-Partum Mental Health; Optimum Time of Fetal Imaging for TSC
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.